SPSara E. Parli

Sara E. Parli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sara E. Parli has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Dina Ali

    Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky, USA

    2 shared publications
  • Abigail Leonhard

    Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA

    1 shared publication
  • Alexandra Wiegand

    Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky, USA

    1 shared publication
  • Alison Woodworth

    Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine , Lexington, Kentucky

    1 shared publication
  • Allison M. Kenneally

    Department of Pharmacy Services, University of Kentucky Healthcare, Lexington, Kentucky, USA

    1 shared publication
  • Aric Schadler

    Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA

    1 shared publication

Latest Publications

  • Assessment of Therapeutic Approaches: Necrotizing Soft Tissue Infections and the Choice Between Vancomycin + Clindamycin and Linezolid

    by Joanna Nixon, Sara E. Parli, Jacqueline M. Bishop, Katie B. Olney, Jeremy VanHoose, Alexandra Wiegand, Dina Ali, Courtney Bradley, Zachary D. Warriner, Abigail Leonhard, et al.

    Background: Necrotizing skin and soft tissue infections (NSTIs) are life threatening, requiring antibiotic agents and surgical intervention. Clindamycin or linezolid is recommended as an adjunct therapy for toxin mediation; however, limited data are comparing clindamycin-based to linezolid-based regimens in NSTI. Methods: This single-center retrospective study included adults with NSTI admitted to the intensive care unit (ICU) at the University of Kentucky HealthCare for surgical debridement between January 2017 and June 2023. Patients were excluded if they received antibiotic agents for Results: A total of 242 patients were included with 199 receiving clindamycin and 43 receiving linezolid. There was no difference observed in the number of surgical debridements between the clindamycin and linezolid cohorts ([2.0 (2, 4) vs. 3.0 (2, 4)]; p = 0.219). The multi-variable regression identified independent parameters that predicted a significant increase in number of debridements included sequential organ failure assessment score (1.03 [1.003, 1.047]; p = 0.028), culture(s) positive for Streptococcus anginosus, Streptococcus constellatus, or Streptococcus intermedius (1.309 [1.042, 1.629]; p = 0.018), and Bacteroides spp. (1.301 [1.048, 1.602]; p = 0.015). No differences were observed in AKI ([53.8% vs. 60.8%], p = 0.424), ICU stay ([5.3 vs. 6.1 d]; p = 0.399), or antibiotic duration between vancomycin, clindamycin, and linezolid ([5.6 vs. 5.6 vs. 6.7 d]; p = 0.683), respectively. Conclusions: Linezolid resulted in a similar number of surgical debridements compared with clindamycin in NSTI patients.


  • Evaluation of Antibiotic Duration after Surgical Debridement of Necrotizing Soft Tissue Infection

    by Allison M. Kenneally, Zachary Warriner, Jeremy D. VanHoose, Dina Ali, Emily J. McCleary, Dan L. Davenport, Sara E. Parli

    Background: Necrotizing soft tissue infection (NSTI) is known to be a medical emergency with high morbidity and mortality. Guidelines do not specify the optimal duration of antibiotic agents after completion of surgical debridements of NSTI, which has created variable practice. It was hypothesized that patients with NSTI who receive 48 hours or less of post-operative antibiotic agents after final debridement have similar rates of subsequent intervention or infection recurrence, suggesting that a shorter duration of antibiotic agents may treat NSTI adequately after final surgical debridement. Patients and Methods: This was a retrospective study including adults with NSTI identified through International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), and Current Procedural Terminology (CPT) codes admitted to one academic institution between January 1, 2010 and July 31, 2020. Demographics, surgical practices, antibiotic practices, and clinical outcomes including inpatient mortality, hospital length of stay (LOS), intensive care unit (ICU) LOS, total antibiotic days, necrotizing infection clinical composite end point (NICCE) success, and infection recurrence were compared based on the duration of antibiotic agents after final debridement. Results: Three hundred twenty-two patients with NSTI were included and baseline characteristics and clinical severity markers were well balanced between the two groups. In 71 patients (22%) who received less than 48 hours of antibiotic agents after final debridement there was no difference in recurrence (1.4% vs. 3.6%; p = 0.697), mortality (1.4% vs. 4.4%; p = 0.476), or ICU LOS (1 vs. 2 days; p = 0.300], but they did have a shorter hospital LOS (7 vs. 10 days; p = 0.011). Conclusions: Shorter duration of antibiotic therapy after final surgical debridement of NSTI may be appropriate in patients without another indication for antibiotic agents.


  • Asystole Following Concomitant Intravenous Administration of Neostigmine and Dexmedetomidine in a Patient With Acute Colonic Pseudo-Obstruction

    by Carolyn Magee Bell, Levi D. Procter, Sara E. Parli

    Acute colonic pseudo-obstruction (ACPO) is a condition characterized by acute dilation of the large bowel without evidence of mechanical obstruction that occurs in a variety of hospitalized patients with many predisposing factors. Management includes supportive care and limitation of offending medications with mainstays of treatment of neostigmine administration and colonic decompression. We report the case of a critically ill patient with ACPO who experienced bradycardia and a brief episode of asystole when receiving concomitant dexmedetomidine and neostigmine infusions but who later remained hemodynamically stable when receiving propofol and neostigmine infusions. The bradycardia and associated hemodynamic instability experienced while on dexmedetomidine and neostigmine infusions were rapidly corrected with atropine and cessation of offending agents. Because ACPO is encountered frequently and the use of dexmedetomidine as a sedative agent in the ICU is increasing, practitioners should be aware of the additive risk of bradycardia and potential for asystole with the combination of neostigmine and dexmedetomidine. Electronic drug interaction databases should be updated and drug information sources should include a drug-drug interaction between dexmedetomidine and neostigmine to reduce the likelihood of concomitant administration.


  • Procalcitonin: Usefulness in Acute Care Surgery and Trauma

    by Sara E. Parli, Grishma Trivedi, Alison Woodworth, Phillip K. Chang

    Background: Procalcitonin (PCT) is a serum biomarker currently suggested by the Surviving Sepsis Campaign to aid in determination of the appropriate duration of therapy in sepsis patients. We review the use of procalcitonin in patients after trauma or acute care surgery. Method: A MEDLINE search via PubMed was performed using the combination of “procalcitonin” and “humans” and “injuries, trauma,” “wounds and injuries,” or “wounds.” Studies of burn patients, children, other biomarkers, and non-acute care surgery were excluded. Results: Procalcitonin may be useful in identifying infection in trauma and post-operative acute care surgery. However, heterogenity exists among patients, and surgery and trauma alone elevate PCT even in the absence of infection. Conclusions: Although trends in PCT concentrations may offer insight, no standard approach can be recommended currently.


  • Open Access

    Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery

    by Sara E. Parli, Melissa L. Thompson Bastin, Daniel A. Lewis

    Purpose.To report the ability to remove serum dabigatran using continuous renal replacement therapy (CRRT) in a patient with life-threatening bleeding.Summary.A 77-year-old female with history of atrial fibrillation who takes dabigatran for stroke prevention presented with abdominal pain. Patient was found to have bleeding and possible mesenteric ischemia and was taken to the operating room and had continued bleeding postoperatively. CRRT was initiated for the removal of any remaining dabigatran, with serum dabigatran levels collected to evaluate removal of dabigatran with CRRT. This patient had an increased dabigatran level prior to intervention, which decreased to an undetectable level after use of CRRT. Greater than 80% of the drug was removed due to 4 hours of CRRT and residual kidney function. Reversal of dabigatran is an area of current research with recent FDA approval of idarucizumab for use.Conclusion.Bleeding may occur as a result of the use of dabigatran and change in patient’s clinical condition. Use of CRRT may be an option in removing serum dabigatran in the case of a life-threatening bleed.